Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT05530655Phase 1Recruiting
- Sponsor
- University of Rochester
- Start
- Feb 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lisinopril in acute radiation syndrome (ARS) (2 arms), sponsored by University of Rochester. Primary endpoints: Mean change in Expanded Prostate Index Composite score at 12 months, Change in the percentage of patients with positive blood test in urine at 12 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
lisinopril
03
Conditions
acute radiation syndrome (ARS)
Beyond the preview
Go deeper on NCT05530655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530655.